Literature DB >> 18253146

Exposure-response analysis for spontaneously reported dizziness in pregabalin-treated patient with generalized anxiety disorder.

K Ito1, Mm Hutmacher, J Liu, R Qiu, B Frame, R Miller.   

Abstract

To describe the pregabalin exposure-adverse event (AE) (dizziness) relationship in patients with generalized anxiety disorder, separate models were developed for the incidence of AE and for the conditional severity of AE, given that an AE has occurred using patient data from six clinical studies. The incidence component was modeled using a nonlinear logistic regression model. The conditional severity component was modeled as an ordered categorical variable with a proportional odds model to capture the severity on any given day. A Markov element was introduced to account for the correlation between neighboring observations. The proportional odds model including a time course of appearance and disappearance of AE could adequately describe the time course of probability of dizziness. Incorporating a transition model including Markov elements improved the model fit and greatly improved the predictability of the time course of probability of dizziness.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18253146     DOI: 10.1038/sj.clpt.6100491

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  10 in total

1.  Implementation and evaluation of the SAEM algorithm for longitudinal ordered categorical data with an illustration in pharmacokinetics-pharmacodynamics.

Authors:  Radojka M Savic; France Mentré; Marc Lavielle
Journal:  AAPS J       Date:  2010-11-11       Impact factor: 4.009

Review 2.  The use of clinical utility assessments in early clinical development.

Authors:  Anis A Khan; Itay Perlstein; Rajesh Krishna
Journal:  AAPS J       Date:  2009-01-16       Impact factor: 4.009

Review 3.  Pharmacodynamic models for discrete data.

Authors:  Ines Paule; Pascal Girard; Gilles Freyer; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2012-12       Impact factor: 6.447

4.  Pharmacodynamic differentiation of lorazepam sleepiness and dizziness using an ordered categorical measure.

Authors:  Mohamed A Kamal; David E Smith; Jack Cook; Douglas Feltner; Allen Moton; Daniele Ouellet
Journal:  J Pharm Sci       Date:  2010-08       Impact factor: 3.534

5.  The impact of tacrolimus exposure on extrarenal adverse effects in adult renal transplant recipients.

Authors:  Olivia Campagne; Donald E Mager; Daniel Brazeau; Rocco C Venuto; Kathleen M Tornatore
Journal:  Br J Clin Pharmacol       Date:  2019-01-04       Impact factor: 4.335

6.  Dopamine D2 receptor occupancy as a predictor of catalepsy in rats: a pharmacokinetic-pharmacodynamic modeling approach.

Authors:  Martin Johnson; Magdalena Kozielska; Venkatesh Pilla Reddy; An Vermeulen; Hugh A Barton; Sarah Grimwood; Rik de Greef; Geny M M Groothuis; Meindert Danhof; Johannes H Proost
Journal:  Pharm Res       Date:  2014-05-03       Impact factor: 4.200

7.  Joint modeling of dizziness, drowsiness, and dropout associated with pregabalin and placebo treatment of generalized anxiety disorder.

Authors:  Bill Frame; Raymond Miller; Matthew M Hutmacher
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-11-08       Impact factor: 2.745

8.  Modelling overdispersion and Markovian features in count data.

Authors:  Iñaki F Trocóniz; Elodie L Plan; Raymond Miller; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-10-02       Impact factor: 2.745

9.  Analysis of Longitudinal-Ordered Categorical Data for Muscle Spasm Adverse Event of Vismodegib: Comparison Between Different Pharmacometric Models.

Authors:  Tong Lu; Yujie Yang; Jin Y Jin; Matts Kågedal
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2020-01-30

10.  Developing Exposure/Response Models for Anticancer Drug Treatment: Special Considerations.

Authors:  D R Mould; A-C Walz; T Lave; J P Gibbs; B Frame
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-01-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.